Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

423 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy.
Schultze A, Torti C, Cozzi-Lepri A, Vandamme AM, Zazzi M, Sambatakou H, De Luca A, Geretti AM, Sonnerborg A, Ruiz L, Monno L, Di Giambenedetto S, Gori A, Lapadula G; European Transmitted Drug Resistance collaboration (EU-TDR). Schultze A, et al. Among authors: torti c. AIDS. 2019 Feb 1;33(2):315-326. doi: 10.1097/QAD.0000000000002046. AIDS. 2019. PMID: 30325769
Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations.
Torti C, Quiros-Roldan E, Regazzi-Bonora M, De Luca A, Lo Caputo S, Di Giambenedetto S, Patroni A, Villani P, Micheli V, Carosi G; Resistance and Dosage Adapted Regimens Study Group of the MASTER Cohort. Torti C, et al. J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):324-6. doi: 10.1097/00126334-200403010-00017. J Acquir Immune Defic Syndr. 2004. PMID: 15076251 Clinical Trial. No abstract available.
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations.
Torti C, Quiros-Roldan E, Monno L, Patroni A, Saracino A, Angarano G, Tinelli C, Mazzotta F, Lo Caputo S, Pierotti P, Carosi G; GenPheRex PhenGen Study Groups of the MASTER Cohort. Torti C, et al. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1104-7. doi: 10.1097/00126334-200408150-00016. J Acquir Immune Defic Syndr. 2004. PMID: 15247566 Clinical Trial. No abstract available.
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
Torti C, Quiros-Roldan E, Monno L, Patroni A, Saracino A, Angarano G, Tinelli C, Lo Caputo S, Tirelli V, Mazzotta F, Carosi G; MASTER Cohort GenPheRex Study Group; MASTER Cohort PhenGen Study Group. Torti C, et al. J Med Virol. 2004 Sep;74(1):29-33. doi: 10.1002/jmv.20142. J Med Virol. 2004. PMID: 15258965
Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen).
Saracino A, Monno L, Locaputo S, Torti C, Scudeller L, Ladisa N, Antinori A, Sighinolfi L, Chirianni A, Mazzotta F, Carosi G, Angarano G. Saracino A, et al. Among authors: torti c. J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1587-98. doi: 10.1097/00126334-200412150-00011. J Acquir Immune Defic Syndr. 2004. PMID: 15577415 Clinical Trial.
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.
Torti C, Quiros-Roldan E, Regazzi M, De Luca A, Mazzotta F, Antinori A, Ladisa N, Micheli V, Orani A, Patroni A, Villani P, Lo Caputo S, Moretti F, Di Giambenedetto S, Castelnuovo F, Maggi P, Tinelli C, Carosi G; RADAR-MASTER Study Group. Torti C, et al. Clin Infect Dis. 2005 Jun 15;40(12):1828-36. doi: 10.1086/429917. Epub 2005 May 12. Clin Infect Dis. 2005. PMID: 15909273 Clinical Trial.
423 results